INDP
Indaptus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.22
+5.17%Sep 4, 2026, 20:14 UTC
Tim Ruan resigned as Director of the Board of Directors of Indaptus Therapeutics, Inc., effective September 2, 2026.
Sep 1, 2026, 11:31 UTC
Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright & Co., LLC, allowing the company to issue and sell common stock with an aggregate maximum offering price of up to $100,000,000.
Aug 13, 2026, 00:00 UTC
Indaptus Therapeutics reported a net loss of $1.79 million for Q2 2026, with diluted EPS of -$0.02, and total operating expenses of $1.81 million.
Jun 24, 2026, 00:00 UTC
Indaptus Therapeutics, Inc. completed a private placement of 20,000,000 shares of common stock for gross proceeds of $12,000,000 on June 17, 2026.
Jun 5, 2026, 00:00 UTC
Walt A. Linscott, Esq. resigned as Chief Operating Officer of Indaptus Therapeutics, Inc., effective June 1, 2026.
Jun 5, 2026, 00:00 UTC
Avraham Ben-Tzvi resigned as Director of Indaptus Therapeutics, Inc., effective June 5, 2026.
Jun 5, 2026, 00:00 UTC
David E. Lazar resigned as Director of Indaptus Therapeutics, Inc., effective June 5, 2026.